Nussbaum specializes in treating patients with diabetic eye disease, age-related macular degeneration, and other degenerative and vascular disorders of the retina. He is professor and chairman of the MCG Department of Ophthalmology and co-director of the university’s James and Jean Culver Vision Discovery Institute, where basic and clinician scientists are investigating the diseases that cause blindness and other eye disorders. His own research interests include diabetic retinopathy and macular degeneration.
Nussbaum also serves as associate dean for Ambulatory Practice at MCG, CEO for AU Medical Associates and executive vice president for Clinical Affairs at AU Health Professor and Chair Department of Ophthalmology, Co-Director, Culver Vision Discovery Institute Assistant Dean and Medical Director of Ambulatory Care Services Augusta University. Dr. Nussbaum is a clinical ophthalmologist and holds fellowships in retina/vitreous and vitreo-retinal surgery. His is an associate examiner for the American Board of Ophthalmology, the American Academy of Ophthalmology, the American Medical Association, the Association of University Professors of Ophthalmology, the Retina Society and the Schepens International Society. He is diplomate of the National Board of Medical Examiners and the American Board of Ophthalmology and a fellow of the American College of Surgeons. Since 2000 Castle Connolly has recognized him annually as one of America's Top Doctors.
Areas of Expertise (6)
Age-Related Macular Degeneration
Diabetic Eye Disease
America's Top Doctors (professional)
Dr. Nussbaum has been named to Castle Connolly Ltd. list of America's Top Doctors in ophthalmology - top 1 percent in nation - every year since 2000.
U.S. News Top Doctors (professional)
Among the list of U.S. News Top Doctors
Best Doctors in America (professional)
- National Board of Medical Examiners : Diplomate
- American Board of Ophthalmology : Diplomate
- American College of Surgeons : Fellow
Media Appearances (4)
AU Health expects to break even after 2017 loss
The Augusta Chronicle print
The Augusta University health system is on track to break even when its fiscal year ends in June. Officials with the enterprise say the health system isn’t working harder – it’s working smarter. The system is beginning to see the fruits of a cost-cutting and realignment plan put into play late last year. “We’re focused more on what we need to do as docs – specifically access, the quality of patient care (and) volume,” Dr. Julian Nussbaum, an ophthalmologist and CEO of the physicians practice, told the finance committee.
T.W. Josey students attend “Raise Your Sights” event at AU
The Augusta Chronicle online
For Dr. Lori Myles, Thursday’s field trip went beyond a lecture from Dr. Julian Nussbaum, chair of ophthalmology at Augusta University.
Drug Makers Accused of Fixing Prices on Insulin
The New York Times online
A lawsuit filed Monday accused three makers of insulin of conspiring to drive up the prices of their lifesaving drugs, harming patients who were being asked to pay for a growing share of their drug bills.
Augusta University is researching a new drug that might help with diabetes-related blindness
The Augusta Chronicle online
Otis Lowe Jr., prides himself for calling it like he sees it and is upfront with Dr. Julian Nussbaum during a visit Tuesday to the Eye Care Center at AU Medical Center.
Prevalence of HFE mutation in age-related macular degeneration (AMD)Investigative Ophthalmology & Visual Science
2014 Iron is essential in normal retinal function with the highest levels in the choroid, RPE, and photoreceptors. Tissue iron levels increase with age, including the macula.
Targeting neovascularization in ischemic retinopathy: recent advancesExpert Review of Ophthalmology
2014 Pathological retinal neovascularization (RNV) is a common microvascular complication in several retinal diseases including retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration and central vein occlusion. The current therapeutic modalities of RNV are invasive and although they may slow or halt the progression of the disease, they are unlikely to restore normal acuity.
Pronerve Growth Factor Induces Angiogenesis via Activation of TrkA: Possible Role in Proliferative Diabetic RetinopathyJournal of Diabetes Research
2013 Proliferative diabetic retinopathy (PDR) is the leading cause of blindness in working age Americans. We demonstrated that diabetes disturbs the homeostasis of nerve growth factor (NGF) resulting in accumulation of its precursor proNGF.